On the other hand, AnxA2 peptides presented by MHC class II-positive cancer cells activate antigen-specific T cells and consequently produce an immune response that can be exploited in immunotherapy (Heinzel et al., 2001; Zheng and Jaffee, 2012; Weyd, 2016). Here, ANXA2 is linked to cancer.